Assessing Ocular Surface Changes After Changing Glaucoma Medications

This study has been completed.

Sponsors and Collaborators:	University of Colorado at Denver and Health Sciences Center Douglas L. Mackenzie
Information provided by:	University of Colorado at Denver and Health Sciences Center
ClinicalTrials.gov Identifier:	NCT00554411

Purpose

hypothesis: changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.

Condition	Intervention
Glaucoma Monotherapy With Xalatan From 1 to 18 Months Ocular Surface Disease	Drug: Travatan Z

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Latanoprost Travoprost

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.

Further study details as provided by University of Colorado at Denver and Health Sciences Center:

Primary Outcome Measures:

measurable change in the tear film break up time

Secondary Outcome Measures:

measurable change in the corneal staining and the Ocular Surface Disease Index

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	50
Study Start Date:	November 2007
Study Completion Date:	May 2008

Intervention Details:

change from Xalatan to Travatan Z

Detailed Description:

Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be record at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

patients will be selected from the ophthalmology clinic of the principal investigator

Criteria

Inclusion Criteria:

on Xalatan monotherapy from 1 t 18 months
18 years of age or older
has been diagnosed with ocular surface disease

Exclusion Criteria:

special populations such as children, pregnant females, prisoners, etc.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00554411

Locations

United States, Colorado
Rocky Mountain Lions Eye Institute
Aurora, Colorado, United States, 80045-0510

Sponsors and Collaborators

University of Colorado at Denver and Health Sciences Center

Douglas L. Mackenzie

Investigators

Principal Investigator:

Malik Kahook, M.D.

Rocky mountain Lions Eye Institute

More Information

Study ID Numbers:	myk07-0757
Study First Received:	November 2, 2007
Last Updated:	December 2, 2008
ClinicalTrials.gov Identifier:	NCT00554411
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Colorado at Denver and Health Sciences Center:

Travatan Z
glaucoma
tear film break up time

Study placed in the following topic categories:

Lacerations
Glaucoma
Eye Diseases
Latanoprost

Travoprost
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Therapeutic Uses
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009